Blood pressure medicine recall across Europe after cancer-causing contaminants found
Carcinogenic chemicals found in tobacco smoke and used in meat curing introduced to high blood pressure treatments manufactured by Chinese supplier
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.UK pharmacists have been told to recall batches of blood pressure medications found to contain cancer-causing contaminants, the medicines watchdog has said.
Directions affect thousands of medicines containing a high blood pressure drug manufactured by two companies, Dexcel Pharma Ltd and Accord Healthcare.
Precautionary measures were launched by the Medicines and Healthcare products Regulatory Agency (MHRA) follow a EU-wide recall after impurities were found in sartan-containing medicines manufactured by a Chinese supplier.
They found traces of nitrate chemicals N-nitrosodimethylamine (NDMA), used in bacon and meat curing but known to be toxic to the liver and cancer-causing at higher doses, and N-Nitrosodiethylamine (NDEA), one of the carcinogens in tobacco smoke.
The latest recall affects four batches of Irbesartan medications, which pharmacists have been told to remove from sale, quarantine all remaining stock and return to suppliers.
Issues may have arisen when the manufacturer changed their processes about seven years ago, but a cause has not been identified.
The MHRA said there was currently no evidence the medicines had caused harm to patients and urged anyone taking them to speak to their doctor before stopping treatments.
Dr Sam Atkinson, MHRA director of the inspection, enforcement and standards division said: “Our highest priority is making sure the medicines you take are safe.
“Our investigation into potential contamination of sartan-containing medicines, including irbesartan, is ongoing."
He added: “At present, there is no evidence that medicines containing NDMA or NDEA have caused any harm to patients.
“Because of the risk associated with suddenly stopping high blood pressure medication, people are advised not to stop any treatments without consulting their doctor or pharmacist.”
Additional reporting by PA
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments